Quest Diagnostics (NYSE:DGX) Price Target Raised to $260.00

Quest Diagnostics (NYSE:DGX) had its price objective raised by Mizuho from $235.00 to $260.00 in a report issued on Friday,Benzinga reports. The firm currently has an outperform rating on the medical research company’s stock.

DGX has been the topic of a number of other research reports. Jefferies Financial Group restated a “buy” rating and issued a $245.00 target price on shares of Quest Diagnostics in a research note on Thursday. Evercore set a $225.00 target price on Quest Diagnostics in a research report on Tuesday, April 21st. Wall Street Zen cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Weiss Ratings raised shares of Quest Diagnostics from a “buy (b)” rating to a “buy (b+)” rating in a report on Thursday, July 9th. Finally, Truist Financial raised their price target on Quest Diagnostics from $225.00 to $250.00 and gave the stock a “hold” rating in a report on Friday. Six analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $231.73.

Quest Diagnostics Stock Up 0.1%

DGX opened at $228.05 on Friday. Quest Diagnostics has a fifty-two week low of $165.78 and a fifty-two week high of $237.78. The firm has a market capitalization of $25.17 billion, a P/E ratio of 24.21, a PEG ratio of 2.61 and a beta of 0.58. The company’s 50-day moving average is $203.23 and its 200 day moving average is $197.76. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.59 and a quick ratio of 1.46.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.82 by $0.30. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The business had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $2.97 billion. During the same period in the prior year, the firm posted $2.62 EPS. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Research analysts expect that Quest Diagnostics will post 11.17 earnings per share for the current fiscal year.

Quest Diagnostics Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, July 22nd. Investors of record on Wednesday, July 8th were issued a dividend of $0.86 per share. This represents a $3.44 dividend on an annualized basis and a yield of 1.5%. The ex-dividend date of this dividend was Wednesday, July 8th. Quest Diagnostics’s dividend payout ratio is 36.52%.

Insider Activity at Quest Diagnostics

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 8,147 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total value of $1,629,400.00. Following the completion of the transaction, the senior vice president directly owned 13,510 shares of the company’s stock, valued at $2,702,000. This trade represents a 37.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the transaction, the chief executive officer owned 132,423 shares of the company’s stock, valued at $25,708,601.22. This trade represents a 7.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.88% of the company’s stock.

Hedge Funds Weigh In On Quest Diagnostics

A number of institutional investors have recently added to or reduced their stakes in the business. Key Financial Inc boosted its position in shares of Quest Diagnostics by 1,728.6% during the 1st quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 121 shares during the last quarter. Quattro Advisors LLC bought a new position in shares of Quest Diagnostics in the fourth quarter worth approximately $25,000. JFS Wealth Advisors LLC raised its stake in Quest Diagnostics by 114.3% in the fourth quarter. JFS Wealth Advisors LLC now owns 150 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 80 shares in the last quarter. Sittner & Nelson LLC purchased a new stake in Quest Diagnostics in the fourth quarter valued at approximately $29,000. Finally, DV Equities LLC bought a new stake in Quest Diagnostics during the fourth quarter valued at approximately $27,000. 88.06% of the stock is currently owned by institutional investors.

Quest Diagnostics News Summary

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Quest Diagnostics posted Q2 results that beat Wall Street expectations on both revenue and earnings, helped by stronger demand for routine diagnostic and preventive testing. The company also raised its full-year 2026 outlook, which investors are reading as evidence that growth is holding up well. Article: Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
• Positive Sentiment: Mizuho raised its price target on DGX to $260 and kept an outperform rating, signaling confidence that the company can still outperform from here. Article: Quest Diagnostics price target raised by Mizuho
• Positive Sentiment: Truist also lifted its target to $250, while Robert W. Baird increased its target to $255, reflecting continued analyst optimism after the earnings beat and raised guidance. Article: Quest Diagnostics price target raised by Truist Financial Corporation
• Neutral Sentiment: Several market commentary pieces highlighted DGX as a momentum stock and noted the shares recently reached a 52-week high. That supports bullish sentiment, but these articles are mostly follow-up coverage rather than a new fundamental catalyst. Article: Are You Looking for a Top Momentum Pick? Why Quest Diagnostics (DGX) Is a Great Choice

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.